浙江沣华医药科技

Zhejiang Fenghua Pharmaceutical Technology is a clinical-stage biotechnology company based in Jiaxing, China, specializing in the development of targeted protein degradation therapies. The company utilizes its proprietary F-PROTAC and molecular glue platforms to address undruggable protein targets in oncology and metabolic diseases. Their lead candidate, FH-2001, is a potent androgen receptor degrader currently in clinical development for the treatment of prostate cancer. Fenghua Pharma's approach combines advanced structural biology with medicinal chemistry to overcome drug resistance and improve patient outcomes. The company is supported by a team of experienced scientists and backed by regional venture capital investors.